Combination of ramucirumab and merestinib for use in treatment of colorectal cancer
AssigneeEli Lilly and Company
InventorsSau-Chi Betty Yan, Richard Anthony Walgren
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a combination of an anti-human VEGFR2 antibody, preferably ramucirumab, and merestinib, or a pharmaceutically acceptable salt thereof, and to methods of using the combination to treat certain disorders, such as colorectal cancer, including advanced or metastatic colorectal cancer and/or local colorectal cancer.
Claims20
A method of treating colorectal cancer in a patient, comprising administering to a patient in need of such treatment an effective amount of an antibody comprising a light chain variable region (LCVR) amino acid sequence of SEQ ID NO:
- 1 and a heavy chain variable region (HCVR) amino acid sequence of SEQ ID NO:
- 2, wherein the antibody binds to VEGFR2, and a compound which is merestinib, or a pharmaceutically acceptable salt thereof.
9-11. (canceled)
14-28. (canceled)
The method of claim 11, wherein the antibody and the compound that is merestinib, or a pharmaceutically acceptable salt thereof, is administered simultaneously, separately, or sequentially.
Dependencies are inferred from the claim text.